Atea PharmaceuticalsI Company Insiders
| AVIR Stock | USD 3.70 0.01 0.27% |
Atea PharmaceuticalsI's insiders are aggressively selling. The analysis of insiders' sentiment of trading Atea PharmaceuticalsInc stock suggests that virtually all insiders are panicking at this time. Atea PharmaceuticalsI employs about 75 people. The company is managed by 22 executives with a total tenure of roughly 92 years, averaging almost 4.0 years of service per executive, having 3.41 employees per reported executive.
| Joseph Patti CEO President CEO, Director |
| Russell Plumb Chairman Executive Chairman of the Board |
Atea PharmaceuticalsI's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-02-01 | Wayne Foster | Disposed 12477 @ 3.84 | View |
Monitoring Atea PharmaceuticalsI's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Atea |
Atea PharmaceuticalsI Management Team Effectiveness
The company has return on total asset (ROA) of (0.1189) % which means that it has lost $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2274) %, meaning that it created substantial loss on money invested by shareholders. Atea PharmaceuticalsI's management efficiency ratios could be used to measure how well Atea PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/18/2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Atea PharmaceuticalsI's Non Current Assets Total are relatively stable compared to the past year. As of 04/18/2024, Non Currrent Assets Other is likely to grow to about 1.5 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.As of 04/18/2024, Common Stock Shares Outstanding is likely to grow to about 85.7 M, though Net Loss is likely to grow to (99.1 M).
Atea PharmaceuticalsI Workforce Comparison
Atea PharmaceuticalsInc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 7,408. Atea PharmaceuticalsI claims roughly 75.0 in number of employees contributing just under 2% to equities under Health Care industry.
Atea PharmaceuticalsI Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea PharmaceuticalsI insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea PharmaceuticalsI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atea PharmaceuticalsI insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.0 | 12 | 12 | 1,691,736 | 499,784 |
| 2020-12-01 | 0.3443 | 21 | 61 | 16,446,374 | 18,528,149 |
Atea PharmaceuticalsI Notable Stakeholders
An Atea PharmaceuticalsI stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atea PharmaceuticalsI often face trade-offs trying to please all of them. Atea PharmaceuticalsI's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atea PharmaceuticalsI's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joseph Patti | President CEO, Director | Profile | |
| Russell Plumb | Executive Chairman of the Board | Profile | |
| Mark Colonnese | CFO, Executive Vice President | Profile | |
| Andrea JD | Executive CFO | Profile | |
| Anne VanLent | Independent Director | Profile | |
| Geoffrey Cox | Independent Director | Profile | |
| John Richard | Independent Director | Profile | |
| Michael Dunne | Independent Director | Profile | |
| Armando Anido | Independent Director | Profile | |
| Michael Dougherty | Independent Director | Profile | |
| CPA CPA | Exec Officer | Profile | |
| XiaoJian Zhou | Executive Development | Profile | |
| Jayanthi Wolf | Executive Affairs | Profile | |
| Wayne CPA | Executive Officer | Profile | |
| Ariyapadi Krishnaraj | Vice Marketing | Profile | |
| JeanPierre Sommadossi | Chairman, Founder | Profile | |
| John Vavricka | Chief Officer | Profile | |
| Nancy Agrawal | Executive Development | Profile | |
| Maria MD | Chief Officer | Profile | |
| Jonae Barnes | Senior Communications | Profile | |
| Keith Pietropaolo | Senior Sciences | Profile | |
| Adel Moussa | Executive Chemistry | Profile |
About Atea PharmaceuticalsI Management Performance
The success or failure of an entity such as Atea PharmaceuticalsInc often depends on how effective the management is. Atea PharmaceuticalsI management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.31) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.23) |
The data published in Atea PharmaceuticalsI's official financial statements usually reflect Atea PharmaceuticalsI's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Atea PharmaceuticalsInc. For example, before you start analyzing numbers published by Atea accountants, it's critical to develop an understanding of what Atea PharmaceuticalsI's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Atea PharmaceuticalsI's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atea PharmaceuticalsI's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Atea PharmaceuticalsI's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atea PharmaceuticalsInc. Please utilize our Beneish M Score to check the likelihood of Atea PharmaceuticalsI's management manipulating its earnings.
Atea PharmaceuticalsI Workforce Analysis
Traditionally, organizations such as Atea PharmaceuticalsI use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atea PharmaceuticalsI within its industry.Atea PharmaceuticalsI Manpower Efficiency
Return on Atea PharmaceuticalsI Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 6.2M | |
| Working Capital Per Employee | 7.4M | |
| Working Capital Per Executive | 25.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.